Evidera experts present at ICPE and are available to meet to discuss your project needs – let’s meet!
Are you attending ICPE in Prague?
Let us help you get the most out of your experience.
Attend our presentations
 
WORKSHOPS
Quantitative Benefit-Risk Assessment
Ataher QS, Postmus D, Hillege HL, Tervonen T
 
Selection of Databases for Pharmacoepidemiology Research
Reynolds MW
 
ORAL PRESENTATIONS
Long-Term Clinical Outcome Following a Myocardial Infarction among the General Population in England
Schultze A, Shah R, Tershakovec A, Hammad TA, Tervonen T, Pinto CA, Lambrelli D
 
Use of Real-World Evidence in Personalized Benefit-Risk Assessment: Closing the Knowledge Gap
Pinto CA, Tervonen T, Marsh K, Lambrelli D, Schultze A, Tershakovec A, Hyacinthe J, Prawitz T, Hammad T
 
Use of Real-World Evidence in Personalized Benefit-Risk Assessment: Detecting Treatment Patterns Using Gaussian Mixture Models
Tervonen T, Pinto CA, Marsh K, Lambrelli D, Schultze A, Prawitz T, Tershakovec A, Hammad T
 
POSTERS
Awareness Strategies, Referral Sources, and Impact on Enrollment in Pregnancy and Lactation Studies
Covington D, Hurst N, Moore T
 
Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Comorbid Cardio-Renal-Metabolic Conditions in the UK
MacLachlan S, Chen H, Hunt P, Repetto E, Vora J
 
Overall Survival and Treatment Patterns among Real-World Patients with Metastatic Non-Small Cell Lung Cancer Not Previously Treated with Systemic Therapy for Advanced Cancer
Simeone JC, Nordstrom BL, Patel K, Klein AB
 
Overall Survival and Treatment Patterns among Real-World Patients with Metastatic Urothelial Carcinoma Treated with First-Line Therapy
Simeone JC, Nordstrom BL, Patel K, Klein AB, Horne L
 
Treatment Guidelines: Adherence and Use Among Type 2 Diabetes Mellitus Providers and Their Patients
Olsson K, Chitnis M, Huelin R
 
Trends in FDA Post-Marketing Commitment Requirements for Pregnancy Registries
Covington D, Bronwen M, Buus R
 
 
Let's connect
 
Stop by booth #1 and enter to win a copy of the new book, Post-Authorization Safety Studies of Medicinal Products: The PASS Book, which includes contributions from several Evidera safety experts.
 
Schedule a meeting
 
 
Are you ready for the new EU HTA Directive?

Evidera understands the significance of this change and we can help you:
 
stay up-to-date on the latest developments
understand the implications for future HTA submissions
adjust your evidence development plans to ensure you are ready for the new regulation
differentiate your product at the country level, where health economics, patient data, and pricing will play a larger role
ensure you are prepared for product launches or indication extensions from 2019 onward

Access resources and latest updates
Evidera
30+ Years of Experience
Real-World Evidence • Patient-Centered Research
Modeling and Meta Research • Market Access • Interventional Studies
Pragmatic Studies • Medical Writing
 

Evidera logo
 
U.S. +1 301 654 9729       
EUR +44 (0) 208 576 5000

info@evidera.com
evidera.com
ppdi.com


Corporate Offices
Boston | Budapest | London | Montreal | Paris | Research Triangle Park | San Francisco | Seattle | Washington, DC